Johanna K Distefano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3969032/publications.pdf

Version: 2024-02-01

95	4,143	94381	123376
papers	citations	37 h-index	61 g-index

96	96	96	6462
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney International, 2012, 82, 1024-1032.	2.6	486
2	Identification of PVT1 as a Candidate Gene for End-Stage Renal Disease in Type 2 Diabetes Using a Pooling-Based Genome-Wide Single Nucleotide Polymorphism Association Study. Diabetes, 2007, 56, 975-983.	0.3	184
3	The interleukin-6 (â^'174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Human Genetics, 2003, 112, 409-413.	1.8	157
4	The Emerging Role of Long Noncoding RNAs in Human Disease. Methods in Molecular Biology, 2018, 1706, 91-110.	0.4	154
5	Functional Characterization of the Plasmacytoma Variant Translocation 1 Gene (PVT1) in Diabetic Nephropathy. PLoS ONE, 2011, 6, e18671.	1.1	146
6	High-throughput SNP detection by using DNA pooling and denaturing high performance liquid chromatography (DHPLC). Human Genetics, 2000, 107, 483-487.	1.8	114
7	Estimation of single nucleotide polymorphism allele frequency in DNA pools by using Pyrosequencing. Human Genetics, 2002, 110, 395-401.	1.8	107
8	IL6 Gene Promoter Polymorphisms and Type 2 Diabetes: Joint Analysis of Individual Participants' Data From 21 Studies. Diabetes, 2006, 55, 2915-2921.	0.3	99
9	The role of non-coding RNAs in diabetic nephropathy: Potential applications as biomarkers for disease development and progression. Diabetes Research and Clinical Practice, 2013, 99, 1-11.	1.1	96
10	NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology, 2020, 161, .	1.4	94
11	Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. Translational Research, 2017, 190, 25-39.e21.	2.2	91
12	Variants in the Plasmacytoma Variant Translocation Gene (PVT1) Are Associated With End-Stage Renal Disease Attributed to Type 1 Diabetes. Diabetes, 2007, 56, 3027-3032.	0.3	89
13	A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Molecular Genetics and Metabolism, 2003, 78, 136-144.	0.5	84
14	Common Polymorphisms in the Adiponectin Gene ACDC Are Not Associated With Diabetes in Pima Indians. Diabetes, 2005, 54, 284-289.	0.3	84
15	Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers, 2019, 11, 486.	1.7	82
16	Pharmacogenetics of Anti-Diabetes Drugs. Pharmaceuticals, 2010, 3, 2610-2646.	1.7	80
17	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	1.8	77
18	Structure and expression of the human MTG8/ETO gene. Gene, 1998, 212, 103-109.	1.0	71

#	Article	IF	Citations
19	Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with typeï¿½2 diabetes mellitus in Pima Indians. Human Genetics, 2003, 113, 377-381.	1.8	71
20	High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver diseaseâ€“related fibrosis. Translational Research, 2015, 166, 304-314.	2.2	69
21	Long Noncoding RNAs as Diagnostic and Therapeutic Targets in Type 2 Diabetes and Related Complications. Genes, 2017, 8, 207.	1.0	69
22	Subcutaneous Abdominal Adipocyte Size, a Predictor of Type 2 Diabetes, Is Linked to Chromosome 1q21â€“q23 and Is Associated with a Common Polymorphism in LMNA in Pima Indians. Molecular Genetics and Metabolism, 2001, 72, 231-238.	0.5	65
23	Variants in the interleukin 6 receptor gene are associated with obesity in Pima Indians. Molecular Genetics and Metabolism, 2003, 80, 338-343.	0.5	65
24	Sequence Variation in PPARG May Underlie Differential Response to Troglitazone. Diabetes, 2005, 54, 3319-3325.	0.3	65
25	Genomeâ€wide SNP genotyping study using pooled DNA to identify candidate markers mediating susceptibility to endâ€stage renal disease attributed to Type 1 diabetes. Diabetic Medicine, 2009, 26, 1090-1098.	1.2	61
26	Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. Non-coding RNA Research, 2017, 2, 129-136.	2.4	57
27	Targeted SNP Genotyping Using the TaqManÂ® Assay. Methods in Molecular Biology, 2011, 700, 77-87.	0.4	55
28	Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals a Core Set of Fibrosis-Specific Genes. Journal of the Endocrine Society, 2018, 2, 710-726.	0.1	55
29	Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis. Cellular and Molecular Life Sciences, 2020, 77, 2079-2090.	2.4	52
30	CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading. Journal of Translational Medicine, 2018, 16, 108.	1.8	50
31	Genome-wide analysis of hepatic lipid content in extreme obesity. Acta Diabetologica, 2015, 52, 373-382.	1.2	47
32	Analysis of Quantitative Lipid Traits in the Genetics of NIDDM (GENNID) Study. Diabetes, 2005, 54, 3007-3014.	0.3	45
33	Perimenopausal Obesity. Journal of Women's Health, 2010, 19, 987-996.	1.5	44
34	ELMO1 variants and susceptibility to diabetic nephropathy in American Indians. Molecular Genetics and Metabolism, 2010, 101, 383-390.	0.5	44
35	The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD). Non-coding RNA, 2018, 4, 18.	1.3	42
36	A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Scientific Reports, 2017, 7, 43238.	1.6	41

#	Article	IF	Citations
37	Micro RNAs in the development of non-alcoholic fatty liver disease. World Journal of Hepatology, 2014, 7, 226.	0.8	40
38	Long noncoding RNAs in the pathogenesis of diabetic kidney disease: implications for novel therapeutic strategies. Personalized Medicine, 2017, 14, 271-278.	0.8	34
39	Meta-Analysis of Genome-Wide Linkage Studies of Quantitative Lipid Traits in Families Ascertained for Type 2 Diabetes. Diabetes, 2007, 56, 890-896.	0.3	33
40	The Arg59Trp variant in ANGPTL8 (betatrophin) is associated with total and HDL-cholesterol in American Indians and Mexican Americans and differentially affects cleavage of ANGPTL3. Molecular Genetics and Metabolism, 2016, 118, 128-137.	0.5	33
41	Pilot Study: Association of Traditional and Genetic Risk Factors and New-Onset Diabetes Mellitus Following Kidney Transplantation. Transplantation Proceedings, 2009, 41, 4172-4177.	0.3	30
42	Towards microRNA-based therapeutics for diabetic nephropathy. Diabetologia, 2013, 56, 444-456.	2.9	29
43	AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p. PLoS ONE, 2019, 14, e0219764.	1.1	29
44	Analysis of the Lamin A/C gene as a candidate for Type II diabetes susceptibility in Pima Indians. Diabetologia, 2001, 44, 779-782.	2.9	27
45	Variants in the gene encoding aldose reductase (AKR1B1) and diabetic nephropathy in American Indians. Diabetic Medicine, 2006, 23, 367-376.	1.2	26
46	Circulating microRNAs in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2016, 10, 161-163.	1.4	26
47	Long Noncoding RNAs and Human Liver Disease. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 1-21.	9.6	25
48	Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. Clinical Epigenetics, 2021, 13, 152.	1.8	25
49	Molecular characterization of the human PEA15 gene on 1q21â€“q22 and association with type 2 diabetes mellitus in Pima Indians. Gene, 2000, 241, 143-148.	1.0	23
50	Analysis of Linkage Disequilibrium between Polymorphisms in the KCNJ9 Gene with Type 2 Diabetes Mellitus in Pima Indians. Molecular Genetics and Metabolism, 2001, 73, 97-103.	0.5	23
51	The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. Pediatric Obesity, 2021, 16, e12759.	1.4	23
52	Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways. Clinical Epigenetics, 2018, 10, 93.	1.8	22
53	Evaluation of the microsomal glutathione S-transferase 3 (MGST3) locus on 1q23 as a Type 2 diabetes susceptibility gene in Pima Indians. Human Genetics, 2003, 113, 353-358.	1.8	21
54	Emerging Roles for miRNAs in the Development, Diagnosis, and Treatment of Diabetic Nephropathy. Current Diabetes Reports, 2013, 13, 582-591.	1.7	20

#	Article	IF	Citations
55	NAFLD in normal weight individuals. Diabetology and Metabolic Syndrome, 2022, 14, 45.	1.2	20
56	Genomic Structure and Expression of Human KCNJ9 (Kir3.3/GIRK3). Biochemical and Biophysical Research Communications, 2000, 274, 302-309.	1.0	19
57	Technological Issues and Experimental Design of Gene Association Studies. Methods in Molecular Biology, 2011, 700, 3-16.	0.4	18
58	Polymorphism in the 3â€² Untranslated Region ofMTG8Is Associated with Obesity in Pima Indian Males. Biochemical and Biophysical Research Communications, 1998, 246, 624-626.	1.0	17
59	Association of variants in the carnosine peptidase 1 gene (CNDP1) with diabetic nephropathy in American Indians. Molecular Genetics and Metabolism, 2011, 103, 185-190.	0.5	17
60	Differential Effects of Multiplicity of Infection on Helicobacter pylori-Induced Signaling Pathways and Interleukin-8 Gene Transcription. Journal of Clinical Immunology, 2011, 31, 60-68.	2.0	17
61	Analysis of SLC19A2, on 1q23.3 Encoding a Thiamine Transporter as a Candidate Gene for Type 2 Diabetes Mellitus in Pima Indians. Molecular Genetics and Metabolism, 2001, 72, 360-363.	0.5	16
62	Angiopoietin-like 8 (ANGPTL8) expression is regulated by miR-143-3p in human hepatocytes. Gene, 2019, 681, 1-6.	1.0	16
63	Molecular Analysis of KCNJ10 on 1q as a Candidate Gene for Type 2 Diabetes in Pima Indians. Diabetes, 2002, 51, 3342-3346.	0.3	16
64	Association of a F479L variant in the cytosolic phospholipase A2 gene (PLA2G4A) with decreased glucose turnover and oxidation rates in Pima Indians. Molecular Genetics and Metabolism, 2003, 79, 61-66.	0.5	15
65	Identification of Susceptibility Genes for Complex Metabolic Diseases. Annals of the New York Academy of Sciences, 2002, 967, 1-6.	1.8	14
66	Cloning, expression and genomic structure of human LMX1A, and variant screening in Pima Indians. Gene, 2002, 290, 217-225.	1.0	13
67	Identification of Novel Clinical Factors Associated with Hepatic Fat Accumulation in Extreme Obesity. Journal of Obesity, 2014, 2014, 1-8.	1.1	13
68	A Modified Precipitation Method to Isolate Urinary Exosomes. Journal of Visualized Experiments, 2015, , 51158.	0.2	13
69	Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p. Cytokine, 2019, 123, 154789.	1.4	13
70	Higher circulating levels of ANGPTL8 are associated with body mass index, triglycerides, and endothelial dysfunction in patients with coronary artery disease. Molecular and Cellular Biochemistry, 2020, 469, 29-39.	1.4	13
71	Meta-analysis of genome-wide linkage studies for quantitative lipid traits in African Americans. Human Molecular Genetics, 2005, 14, 3955-3962.	1.4	12
72	Identification of Genes for Hereditary Hemochromatosis. Methods in Molecular Biology, 2018, 1706, 353-365.	0.4	12

#	Article	IF	Citations
73	Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis. Biochemistry and Biophysics Reports, 2020, 22, 100753.	0.7	9
74	Beyond the Protein-Coding Sequence: Noncoding RNAs in the Pathogenesis of Type 2 Diabetes. Review of Diabetic Studies, 2015, 12, 260-276.	0.5	9
75	Serotonergic involvement in the regulation of prolactin and vasoactive intestinal peptide mRNA expression in the rat anterior pituitary. Molecular and Cellular Endocrinology, 1994, 105, 183-191.	1.6	8
76	miRNA Quantification Method Using Quantitative Polymerase Chain Reaction in Conjunction with C q Method. Methods in Molecular Biology, 2018, 1706, 257-265.	0.4	8
77	Methods for CpG Methylation Array Profiling Via Bisulfite Conversion. Methods in Molecular Biology, 2018, 1706, 233-254.	0.4	7
78	Polymorphism screening of the insulin receptor-related receptor gene (INSRR) on 1q in Pima Indians. Molecular and Cellular Probes, 2001, 15, 223-227.	0.9	6
79	Emerging Role of Long Noncoding RNAs in Perioperative Neurocognitive Disorders and Anesthetic-Induced Developmental Neurotoxicity. Anesthesia and Analgesia, 2021, 132, 1614-1625.	1.1	5
80	Binding of Sequence-Specific Proteins to the 3â€²-Untranslated Region of Vasoactive Intestinal Peptide mRNA. Biochemical and Biophysical Research Communications, 1995, 211, 819-825.	1.0	4
81	Variant screening of PRKAB2, a type 2 diabetes mellitus susceptibility candidate gene on 1q in Pima Indians. Molecular and Cellular Probes, 2002, 16, 421-427.	0.9	4
82	Identification of Disease Susceptibility Alleles in the Next Generation Sequencing Era. Methods in Molecular Biology, 2018, 1706, 3-16.	0.4	4
83	miRNA profiling for the early detection and clinical monitoring of diabetic kidney disease. Biomarkers in Medicine, 2017, 11, 99-102.	0.6	3
84	A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies. Metabolites, 2022, 12, 528.	1.3	3
85	Genome-Wide Scan for CAG/CTG Repeat Expansions in Pimas with Early Onset of Type 2 Diabetes Mellitus. Molecular Genetics and Metabolism, 1999, 66, 62-67.	0.5	2
86	Identification of novel genetic markers and improved treatment options for diabetic kidney disease. Biomarkers in Medicine, 2010, 4, 739-741.	0.6	2
87	High False-Negative Rate for Nonalcoholic Steatohepatitis in Extreme Obesity. Gastroenterology, 2016, 150, 283-284.	0.6	2
88	Development of Targeted Therapies Based on Gene Modification. Methods in Molecular Biology, 2018, 1706, 39-51.	0.4	1
89	CXCL4L1 Promoter Polymorphisms Are Associated with Improved Renal Function in Type 1 Diabetes. Journal of Immunology, 2019, 202, 912-919.	0.4	1
90	Urinary Exosomes as a Potential Source for the Identification of Biomarkers for Kidney Damage: Comparing Methodologies. , 2014, , 1-14.		0

#	Article	IF	Citations
91	The Human Genome Project: Where Are We Now and Where Are We Going?. , 2015, , 7-31.		0
92	Pharmacoepigenetics in Type 2 Diabetes Mellitus. , 2019, , 563-571.		0
93	Urinary Exosomes as Potential Source for Identification of Biomarkers for Kidney Damage: Comparing Methodologies. Biomarkers in Disease, 2015, , 939-954.	0.0	0
94	Long Noncoding RNAs as Drivers of Acquired Chemoresistance in Hepatocellular Carcinoma. RNA Technologies, 2020, , 199-227.	0.2	0
95	Palmitate and Fructose Interact to Induce Human Hepatocytes to Produce Pro-Fibrotic Transcriptional Responses in Hepatic Stellate Cells Exposed to Conditioned Media. Cellular Physiology and Biochemistry, 2020, 54, 1068-1082.	1.1	0